dual TBK1/IKKI inhibitors (Scripps Research Institute)

N/A

Report date: 2025/03/18 18:15:25
NME

Base Information

Drug Namedual TBK1/IKKI inhibitors (Scripps Research Institute)
Drug Alias Namedual TANK binding kinase 1/inhibitor of nuclear factor kappa-B kinase subunit epsilon inhibitors (Scripps Research)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase TBK1 inhibitorsInhibitor of nuclear factor kappa-B kinase subunit epsilon inhibitors
TargetsSerine/threonine-protein kinase TBK1Inhibitor of nuclear factor kappa-B kinase subunit epsilon
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe Scripps Research Institute Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Scripps Research Institute Inc
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A